The goal of management of ARVD is to decrease the incidence of sudden cardiac death.  This raises a clinical dilemma: How to prophylactically treat the asymptomatic patient who was diagnosed during family screening.
A certain subgroup of individuals with ARVD are considered at high risk for sudden cardiac death.  Characteristics associated with high risk of sudden cardiac death include:
Young age
Competitive sports activity
Malignant familial history
Extensive RV disease with decreased<unk><unk>  ejection fraction.
Left<unk>  involvement
Syncope
Episode of<unk>  arrhythmia
Management options include pharmacological, surgical, catheter ablation, and placement of an implantable cardioverter-defibrillator.
Prior to the decision of the treatment option, programmed electrical stimulation in the  electrophysiology laboratory may be performed for additional prognostic information.  Goals of programmed stimulation include:
Assessment of the disease's<unk>  potential
Evaluate the hemodynamic consequences of sustained VT
Determine whether the VT can be interrupted via antitachycardia pacing.
Regardless of the management option chosen, the individual is typically suggested to undergo lifestyle modification, including avoidance of strenuous exercise, cardiac stimulants (ie: caffeine, nicotine, pseudoephedrine) and alcohol.  If the individual wishes to begin an exercise regimen, an exercise stress test may have added benefit.
Arrhythmogenic right ventricular dysplasia medical therapy
Ebsteins anomaly of the tricuspid valve medical therapy
Pulmonary regurgitation surgical therapy
Tetralogy of fallot medical treatment
Pulmonic regurgitation medical therapy
Tricuspid stenosis medical therapy
Hypertrophic cardiomyopathy medical treatment
Hypertrophic cardiomyopathy medical therapy